KDR and neoplasm: Anti-EGFR/VEGFR2 BsAb mimic the functions of both cetuximab and ramucirumab by blocking ligand-mediated activation of EGFR signaling in TNBC cells and inhibited VEGFR2 signaling in HUVEC cells, suggesting that bispecific functionality of anti-EGFR/VEGFR2 BsAb can eliminate the requirement of combining two mAbs to achieve desired anti-tumor effects.